[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619791":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":108,"collaborators":19,"id":110,"slug":111,"hasResults":112,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":9,"eligibilityCriteria":116,"healthyVolunteers":112,"sex":117,"minAge":118,"maxAge":119,"enrollmentInfo":120,"targetDuration":19,"studyType":123,"phases":124,"briefSummary":127,"conditions":128,"keywords":131,"overallStatus":62,"whyStopped":19,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":143},{"fullName":5,"class":6},"Ukko Inc","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"UKK-0018","EXPERIMENTAL","UKK0018 is an immunotherapeutic for the treatment of peanut allergies",[13],"Biological: UKK-0018",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","UKK0018 is an immunotherapeutic treatment of peanut allergies",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Clinical Development Officer","CONTACT","+1 503 915 1400","sharron@ukko.us",[27,46,60,76,91],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Royal Prince Alfred Hospital","NOT_YET_RECRUITING","Camperdown","New South Wales","2050","Australia","AU",{"type":36,"coordinates":37},"Point",[38,39],151.17642,-33.88965,{"lat":39,"lon":38},[42],{"name":43,"role":23,"phone":44,"phoneExt":19,"email":45},"Alex Stoyanov, MD","(02) 9515 7585","Alex.Stoyanov@health.nsw.gov.au",{"facility":47,"status":29,"city":48,"state":49,"zip":50,"country":33,"countryCode":34,"cosmosGeoPoint":51,"geoPoint":55,"contacts":56},"Flinders Medical Center","Bedford Park","South Australia","5042",{"type":36,"coordinates":52},[53,54],138.56815,-35.02204,{"lat":54,"lon":53},[57],{"name":58,"role":23,"phone":19,"phoneExt":19,"email":59},"Syed Ali, MD","Health.ResearchHubCT@sa.gov.au",{"facility":61,"status":62,"city":63,"state":64,"zip":65,"country":33,"countryCode":34,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"The Royal Melbourne Hospital","RECRUITING","Fitzroy","Victoria","3065",{"type":36,"coordinates":67},[68,69],144.97833,-37.79839,{"lat":69,"lon":68},[72],{"name":73,"role":23,"phone":74,"phoneExt":19,"email":75},"Kymble Spriggs","03 9342 7000","AllergyResearch@mh.org.au",{"facility":77,"status":29,"city":78,"state":79,"zip":80,"country":33,"countryCode":34,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"Fiona Stanley Hospital","Perth","Western Australia","6150",{"type":36,"coordinates":82},[83,84],115.8614,-31.95224,{"lat":84,"lon":83},[87],{"name":88,"role":23,"phone":89,"phoneExt":19,"email":90},"Michael O Sullivan, MD","08 6456 2222","fshimmunology.research@health.wa.gov.au",{"facility":92,"status":62,"city":93,"state":94,"zip":95,"country":96,"countryCode":97,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"Pacific Clinical Research Network - Auckland","Takapuna","Auckland","0622","New Zealand","NZ",{"type":36,"coordinates":99},[100,101],174.77583,-36.79167,{"lat":101,"lon":100},[104],{"name":105,"role":23,"phone":106,"phoneExt":19,"email":107},"Enrollment Coordinator","+64 9 242 3321","Auckland@pcrn.co.nz",{"type":109,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100619791","phase-1-ukk-0018-as-an-immunotherapeutic-for-treatment-of-peanut-allergies-100619791",false,"NCT07349212","UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies","A First-in-Human, Ascending Dose, Open-label, Multicenter Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of UKK-0018 in Peanut Allergic Individuals","Inclusion Criteria:\n\n* Adults 18-55 years old\n* documented history of physician-diagnosed peanut allergy\n* positive skin prick test (SPT)\n* screening DBPCFC peanut protein\n* contraception use should be consistent with local regulations\n* capable of providing signed written informed consent\n\nExclusion Criteria:\n\n* asthma based on NHLBI\n* uncontrolled cardiovascular disease\n* chronic disease history\n* exacerbation of dermatological conditions\n* life threatening episodes of anaphylaxis\n* active infections\n* poor physical or blood chemistry\n* immunodeficiency, bleeding disorders, malignancies\n* hypersensitivities to epinephrine, inactive ingredients in therapy\n* pregnant or breast feeding","ALL","18 Years","55 Years",{"count":121,"type":122},40,"ESTIMATED","INTERVENTIONAL",[125,126],"PHASE1","PHASE2","This study will test a new investigational treatment called UKK-0018. UKK-0018 as an immunotherapeutic for the treatment of peanut allergies. The treatment is given by injection and is designed to train the immune system to tolerate peanut exposure over time.",[129,130],"Peanut-Induced Anaphylaxis","Peanut Allergy",[132,133],"peanut","peanut allergy","2026-06-22",{"date":136,"type":137},"2026-06-25","ACTUAL",{"date":139,"type":137},"2026-02-18",{"date":141,"type":122},"2027-11-01",{"name":5,"class":6},5]